Tokyo Tape
Sign in
← BrightPath Biotherapeutics

Annual report

4594.TEDINET S100PTKC
Period2019-04-01 → 2020-03-31
Filed2022-12-19
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amends S100J2Q6.

Key figures · 87
MetricValuePeriodScopeSource row
Revenue¥11m2019-04-01 → 2020-03-31StandaloneNet sales
Revenue¥156m2018-04-01 → 2019-03-31StandaloneNet sales
Revenue¥354m2017-04-01 → 2018-03-31dStandaloneNet sales (5-year summary)
Revenue¥530m2016-04-01 → 2017-03-31dStandaloneNet sales (5-year summary)
Revenue¥823m2015-04-01 → 2016-03-31dStandaloneNet sales (5-year summary)
Operating income−¥1.8bn2019-04-01 → 2020-03-31StandaloneOperating income
Operating income−¥1.7bn2018-04-01 → 2019-03-31StandaloneOperating income
Ordinary income−¥1.8bn2019-04-01 → 2020-03-31StandaloneOrdinary income
Ordinary income−¥1.7bn2018-04-01 → 2019-03-31StandaloneOrdinary income
Ordinary income−¥1.6bn2017-04-01 → 2018-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.6bn2017-04-01 → 2018-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.1bn2016-04-01 → 2017-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.1bn2016-04-01 → 2017-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥993m2015-04-01 → 2016-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.9bn2019-04-01 → 2020-03-31StandaloneIncome before income taxes
Profit before tax−¥1.9bn2018-04-01 → 2019-03-31StandaloneIncome before income taxes
Net income (owners)−¥1.6bn2017-04-01 → 2018-03-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.1bn2016-04-01 → 2017-03-31dStandaloneProfit loss attributable to owners of parent (5-year summary)
Net income−¥1.9bn2019-04-01 → 2020-03-31StandaloneProfit loss
Net income−¥1.9bn2018-04-01 → 2019-03-31StandaloneProfit loss
Net income−¥1.6bn2017-04-01 → 2018-03-31dStandaloneNet income loss (5-year summary)
Net income−¥1.1bn2016-04-01 → 2017-03-31dStandaloneNet income loss (5-year summary)
Net income−¥994m2015-04-01 → 2016-03-31dStandaloneNet income loss (5-year summary)
Total assets¥3.5bnat 2020-03-31StandaloneAssets
Total assets¥5.3bnat 2019-03-31StandaloneAssets
Total assets¥7.2bnat 2018-03-31dStandaloneTotal assets (5-year summary)
Total assets¥7.2bnat 2018-03-31dStandaloneTotal assets (5-year summary)
Total assets¥5.4bnat 2017-03-31dStandaloneTotal assets (5-year summary)
Total assets¥5.4bnat 2017-03-31dStandaloneTotal assets (5-year summary)
Total assets¥2.9bnat 2016-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥239mat 2020-03-31StandaloneLiabilities
Total liabilities¥208mat 2019-03-31StandaloneLiabilities
Net assets / equity¥3.2bnat 2020-03-31StandaloneNet assets
Net assets / equity¥5.1bnat 2019-03-31StandaloneNet assets
Net assets / equity¥7.0bnat 2018-03-31dStandaloneNet assets
Net assets / equity¥5.2bnat 2017-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥5.2bnat 2017-03-31dStandaloneNet assets (5-year summary)
Net assets / equity¥2.7bnat 2016-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥3.0bnat 2020-03-31StandaloneCash and deposits
Cash and deposits¥4.9bnat 2019-03-31StandaloneCash and deposits
Cash & equivalents¥3.0bnat 2020-03-31StandaloneCash and cash equivalents
Cash & equivalents¥4.9bnat 2019-03-31StandaloneCash and cash equivalents
Cash & equivalents¥6.5bnat 2018-03-31dStandaloneCash and cash equivalents
Cash & equivalents¥6.5bnat 2018-03-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥5.0bnat 2017-03-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥2.6bnat 2016-03-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.8bn2019-04-01 → 2020-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.5bn2018-04-01 → 2019-03-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥1.6bn2017-04-01 → 2018-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.1bn2016-04-01 → 2017-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥909m2015-04-01 → 2016-03-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥107m2019-04-01 → 2020-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥185m2018-04-01 → 2019-03-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥112m2017-04-01 → 2018-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥97m2016-04-01 → 2017-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥32m2015-04-01 → 2016-03-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥9m2019-04-01 → 2020-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥16m2018-04-01 → 2019-03-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥3.3bn2017-04-01 → 2018-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥3.6bn2016-04-01 → 2017-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥2.7bn2015-04-01 → 2016-03-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-44.22019-04-01 → 2020-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-44.952018-04-01 → 2019-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-41.252017-04-01 → 2018-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-32.742016-04-01 → 2017-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-35.282015-04-01 → 2016-03-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥75.49at 2020-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥119.66at 2019-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥164.78at 2018-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥139.17at 2017-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥85.53at 2016-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio91.5%at 2020-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio94.7%at 2019-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio95.3%at 2018-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio95.2%at 2018-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio95.8%at 2017-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio94.6%at 2016-03-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued42,101,000at 2020-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued41,993,500at 2019-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued41,835,400at 2018-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued37,218,400at 2017-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued31,807,700at 2016-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees44at 2020-03-31StandaloneNumber of employees
Employees42at 2019-03-31StandaloneNumber of employees
Employees42at 2018-03-31dStandaloneNumber of employees
Employees37at 2017-03-31dStandaloneNumber of employees
Employees21at 2016-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

All source rows · 837
ItemContextValueUnit
Payments for purchase of treasury subscription right to share fin cfPrior1YearDuration_NonConsolidatedMember－JPY
Payments for purchase of treasury subscription right to share fin cfCurrentYearDuration_NonConsolidatedMember-2228000JPY
Net cash provided by used in financing activitiesPrior1YearDuration_NonConsolidatedMember15810000JPY
Net cash provided by used in financing activitiesCurrentYearDuration_NonConsolidatedMember8521000JPY
Net increase decrease in cash and cash equivalentsPrior1YearDuration_NonConsolidatedMember-1626876000JPY
Net increase decrease in cash and cash equivalentsCurrentYearDuration_NonConsolidatedMember-1882820000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember6528053000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember4901177000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember4901177000JPY
Cash and cash equivalentsCurrentYearInstant_NonConsolidatedMember3018356000JPY
Accumulated depreciation ppe by groupPrior1YearInstant_NonConsolidatedMember-222671000JPY
Accumulated depreciation ppe by groupCurrentYearInstant_NonConsolidatedMember-281332000JPY
Research and development expenses included in general and administrative expenses and manufacturing cost for current periodPrior1YearDuration_NonConsolidatedMember1387674000JPY
Research and development expenses included in general and administrative expenses and manufacturing cost for current periodCurrentYearDuration_NonConsolidatedMember1484854000JPY
Directors compensations sgaPrior1YearDuration_NonConsolidatedMember62425000JPY
Directors compensations sgaCurrentYearDuration_NonConsolidatedMember58300000JPY
Salaries and allowances sgaPrior1YearDuration_NonConsolidatedMember60737000JPY
Salaries and allowances sgaCurrentYearDuration_NonConsolidatedMember77151000JPY
Retirement benefit expenses sgaPrior1YearDuration_NonConsolidatedMember1005000JPY
Retirement benefit expenses sgaCurrentYearDuration_NonConsolidatedMember1806000JPY
Depreciation sgaPrior1YearDuration_NonConsolidatedMember868000JPY
Depreciation sgaCurrentYearDuration_NonConsolidatedMember177000JPY
Compensations sgaPrior1YearDuration_NonConsolidatedMember26301000JPY
Compensations sgaCurrentYearDuration_NonConsolidatedMember24790000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember1387674000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember1484854000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書の訂正報告書（2022年12月19日付けの訂正報告書の添付インラインXBRL）
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2022-12-19
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第17期(自　2019年４月１日　至　2020年３月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)ブライトパス・バイオ株式会社
Company name in english cover pageFilingDateInstantBrightPath Biotherapeutics Co., Ltd.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　永井 健一
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番22号
Telephone number address of registered headquarter cover pageFilingDateInstant044-440-3939
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)管理部長　竹下 陽一
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都千代田区麹町二丁目２番地４
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03-5840-7697(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)管理部長　竹下 陽一
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE31851
Fund codeFilingDateInstant－
Security codeFilingDateInstant45940
Filer name in japaneseFilingDateInstant
Original text (Japanese)ブライトパス・バイオ株式会社
Filer name in englishFilingDateInstantBrightPath Biotherapeutics Co., Ltd
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2019-03-31pass rounding
balance sheet identitynon_consolidated 2020-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2018-03-31pass
statement vs summary · net assetsnon_consolidated 2019-03-31pass
statement vs summary · net assetsnon_consolidated 2020-03-31pass
statement vs summary · operating cash flownon_consolidated 2018-04-01/2019-03-31pass
statement vs summary · operating cash flownon_consolidated 2019-04-01/2020-03-31pass
statement vs summary · revenuenon_consolidated 2018-04-01/2019-03-31pass
statement vs summary · revenuenon_consolidated 2019-04-01/2020-03-31pass
statement vs summary · total assetsnon_consolidated 2019-03-31pass
statement vs summary · total assetsnon_consolidated 2020-03-31pass